Enanta Pharmaceuticals Announces Data Presentations at The International Liver Congress™ 2018
March 28 2018 - 7:30AM
Business Wire
- Oral presentation to feature
preclinical data on novel core inhibitor EP-027367 targeting
hepatitis B virus
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and
development-focused biotechnology company dedicated to creating
small molecule drugs for viral infections and liver diseases, today
announced that data from Enanta’s wholly-owned development
programs, including EP-027367, one of Enanta’s novel core
inhibitors in preclinical testing for hepatitis B virus (HBV), and
EDP-305, an FXR agonist in development for non-alcoholic
steatohepatitis (NASH) and primary biliary cholangitis (PBC), have
been accepted for presentation at The International Liver Congress™
(ILC) 2018, April 11-15, in Paris, France.
EP-027367, one of several core inhibitors Enanta is evaluating,
has been selected for an oral presentation. There will also be
three posters on EDP-305, which is currently in a Phase 2 study for
NASH and a Phase 2 study for PBC. The U.S. Food and Drug
Administration has granted EDP-305 Fast Track designation for the
treatment of NASH patients with liver fibrosis and Fast Track
designation for the treatment of patients with PBC.
In addition, several abstracts from AbbVie will be presented on
their HCV regimens containing glecaprevir/pibrentasvir and marketed
under the tradenames MAVYRET™ (U.S.) and MAVIRET™ (ex-U.S.).
Glecaprevir is Enanta’s second protease inhibitor discovered and
commercialized through its protease inhibitor collaboration with
AbbVie.
The full ILC 2018 scientific program as well as the abstracts
can be found at http://ilc-congress.eu/. Further details will be
available at the time of these presentations.
Oral Presentation:
- Thursday, April 12, 17:45 - 18:00
CETPS-032 - “Discovery of a novel HBV core inhibitor EP-027367
with potent antiviral activity both in vitro and in a humanized
mouse model” (M.Vaine, S.Clugston, J.Kass, X. Gao, H. Cao, W. Li,
X. Peng, L.J. Jiang, K. Daniels, Y. Qiu, Y.S. Or, K. Lin)
Poster PresentationsThursday, April 12, 09:00 - 17:00
CET
- THU-469 - “EDP-305 modulates
lipoprotein metabolism via distinct chromatin and microRNA
regulatory mechanisms” (M. Roqueta-Rivera, M.D. Chau, K. Garlick,
Y. Li, G. Wang, Y.S. Or, and L.J. Jiang)
Friday, April 13, 09:00 - 17:00 CET
- FRI-084 - “EDP-305, a highly selective
and potent farnesoid X receptor agonist, favorably regulates the
expression of key fibrogenic genes in vitro and in vivo” (Y. Li,
J.Y. Shang, M.D. Chau, M. Roqueta-Rivera, K. Garlick, P. An, K.
Vaid, G. Wang, Y. Popov, Y. S. Or, and L. J. Jiang)
- FRI-489 - “Pharmacokinetics,
pharmacodynamics, and safety of EDP-305, in healthy and presumptive
NAFLD subjects” (A. Ahmad, K. Sanderson, D. Dickerson, N.
Adda)
About EnantaEnanta Pharmaceuticals has used its robust,
chemistry-driven approach and drug discovery capabilities to become
a leader in the discovery of small molecule drugs for the treatment
of viral infections and liver diseases. Two protease inhibitors,
glecaprevir and paritaprevir, discovered and developed through
Enanta’s collaboration with AbbVie, have now been approved in
jurisdictions around the world as part of AbbVie’s direct-acting
antiviral (DAA) regimens for the treatment of hepatitis C virus
(HCV) infection, including the regimens marketed as MAVYRET™ (U.S.)
and MAVIRET™ (ex-U.S.) (glecaprevir/pibrentasvir) and VIEKIRA PAK®
(paritaprevir/ritonavir/ombitasvir/dasabuvir) (U.S.) and VIEKIRAX®
(paritaprevir/ritonavir/ombitasvir) (ex-U.S.).
Royalties from the AbbVie collaboration are helping to fund
Enanta’s research and development efforts, which are currently
focused on the following disease targets: non-alcoholic
steatohepatitis (NASH), primary biliary cholangitis (PBC),
respiratory syncytial virus (RSV) and hepatitis B virus (HBV).
Please visit www.enanta.com for more information.
Forward Looking Statements DisclaimerThis press release
contains forward-looking statements, including statements with
respect to the prospects for continuing royalties from the AbbVie
collaboration and the prospects for Enanta’s further development of
EDP-305 and EP-027367. Statements that are not historical facts are
based on management’s current expectations, estimates, forecasts
and projections about Enanta’s business and the industry in which
it operates and management’s beliefs and assumptions. The
statements contained in this release are not guarantees of future
performance and involve certain risks, uncertainties and
assumptions, which are difficult to predict. Therefore, actual
outcomes and results may differ materially from what is expressed
in such forward-looking statements. Important factors and risks
that may affect actual results include: the marketing and
commercialization efforts of others with respect to treatment
regimens for HCV that are competitive with MAVYRET/MAVIRET;
regulatory and reimbursement actions affecting MAVYRET/MAVIRET, any
competitive regimen, or both; the development risks of Enanta’s
early stage discovery efforts in NASH, PBC, RSV and HBV; Enanta’s
lack of clinical development experience; Enanta’s need to attract
and retain senior management and key scientific personnel; the need
to obtain and maintain patent protection for glecaprevir and
Enanta’s other product candidates and avoid potential infringement
of the intellectual property rights of others; and other risk
factors described or referred to in “Risk Factors” in Enanta’s most
recent Form 10-Q for the fiscal quarter ended December 31, 2017 and
other periodic reports filed more recently with the Securities and
Exchange Commission. Enanta cautions investors not to place undue
reliance on the forward-looking statements contained in this
release. These statements speak only as of the date of this
release, and Enanta undertakes no obligation to update or revise
these statements, except as may be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180328005548/en/
Investor ContactEnanta Pharmaceuticals, Inc.Carol Miceli,
617-607-0710cmiceli@enanta.comorMedia ContactMacDougall
Biomedical CommunicationsKari Watson,
781-235-3060kwatson@macbiocom.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Jul 2023 to Jul 2024